Latest Ratios: P/E Ratio 10.8x · EV/EBITDA N/A · ROE N/A. (2007–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.1B | $575M | $205M | $142M | $401M | $817M | $698M | $541M | $885M | $401M |
| Enterprise Value | $1.3B | $1.3B | $778M | $560M | $473M | $648M | $1.1B | $889M | $687M | $966M | $479M |
| P/E Ratio → | 10.79 | — | — | — | 4.91 | — | — | — | — | — | — |
| P/S Ratio | 14.16 | — | — | — | — | — | — | 6.24 | 18.12 | 13.65 | 9.64 |
| P/B Ratio | — | — | — | — | 1.65 | 16.86 | — | — | 0.83 | — | — |
| P/FCF | — | — | — | 2.76 | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 2.75 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | 7.95 | 22.99 | 14.90 | 11.51 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | 7.53 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 97.6% | 98.3% | 98.3% | 96.6% |
| Operating Margin | — | — | — | — | — | — | — | -56.7% | -375.7% | -67.7% | -130.4% |
| Net Profit Margin | — | — | — | — | — | — | — | -75.6% | -424.4% | -82.5% | -160.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -388.2% | 86.6% | -468.5% | — | -31.2% | -39.2% | — | — |
| ROA | -1.1% | -1.1% | -47.9% | -24.3% | 9.4% | -37.1% | -86.8% | -72.5% | -119.4% | -58.3% | -114.8% |
| ROIC | -142.5% | -142.5% | -72.4% | -33.1% | -35.6% | -63.8% | -107.2% | -10.8% | -19.3% | -55.4% | -130.0% |
| ROCE | -55.2% | -55.2% | -64.8% | -42.2% | -39.8% | -67.8% | -139.0% | -90.5% | -151.0% | -62.2% | -129.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 3.99 | 14.63 | — | — | 0.23 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | 3.86 | 10.39 | — | — | 0.22 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | 4.77 | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -6.40 | -4.67 | -7.02 | -8.74 | -6.34 | -2.73 | -7.60 | -3.85 | -7.54 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.76 | 2.76 | 1.69 | 4.09 | 3.25 | 4.79 | 4.12 | 1.87 | 2.41 | 4.12 | 3.75 |
| Quick Ratio | 2.76 | 2.76 | 1.69 | 4.09 | 3.25 | 4.79 | 4.08 | 1.85 | 1.00 | 4.10 | 3.68 |
| Cash Ratio | 2.20 | 2.20 | 1.13 | 3.22 | 1.43 | 3.04 | 3.67 | 1.10 | 1.62 | 3.18 | 2.82 |
| Asset Turnover | — | — | — | — | — | — | — | 0.82 | 0.31 | 0.56 | 0.62 |
| Inventory Turnover | — | — | — | — | — | — | 1.19 | 2.31 | 0.01 | 2.43 | 1.25 |
| Days Sales Outstanding | — | — | — | — | — | — | — | 114.87 | 278.85 | 96.53 | 105.57 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.3% | — | — | — | 20.4% | — | — | — | — | — | — |
| FCF Yield | — | — | — | 36.2% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 2.1% | 2.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 2.1% | 2.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $64M | $58M | $63M | $63M | $62M | $57M | $50M | $49M | $46M | $40M |
Includes 30+ ratios · 19 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OMER stock.
Omeros Corporation's current P/E ratio is 10.8x. The historical average is 4.9x. This places it at the 100th percentile of its historical range.
Based on historical data, Omeros Corporation is trading at a P/E of 10.8x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Critical liquidity and regulatory risk
Metrics are mathematically derived from official filings.
Valuation Reflects Binary Pipeline Outcomes
Omeros's forward P/E of 21.11x appears deceptively low for a pre-profit biotech, as it is based on speculative forward earnings estimates that hinge entirely on the successful commercial ramp of YARTEMLEA and the regulatory fate of narsoplimab, according to current market consensus.
The forward P/E multiple is not anchored to a sustainable earnings base but rather to a single quarter of launch revenue and projected future milestones. This valuation framework is highly sensitive to clinical and regulatory catalysts, making it a poor indicator of intrinsic value. Investors should focus on the EV/EBITDA of 14.65x, which better reflects the company's enterprise value relative to its nascent operating income, but even this metric is volatile given the company's history of negative EBITDA.
Royalty Margins Mask Structural Operating Losses
While Omeros reported a 97.2% gross margin in Q2 2026, this near-perfect figure is a function of its royalty-based revenue stream and is entirely consumed by R&D and SG&A expenses, resulting in a net margin of 46.4% that is heavily distorted by non-cash items.
The high gross margin is a structural feature of the Omidria royalty agreement, not an indicator of operational efficiency. The true earning power is obscured by the company's massive R&D burn, which totaled $13.8 million in the same quarter. The positive net margin is likely driven by non-cash fair value adjustments on financial instruments rather than sustainable operational profitability, as evidenced by the operating cash flow being only 31% of net income.
Negative Returns Persist Despite Revenue Inflection
Omeros's ROIC of 0.0% in Q2 2026, while an improvement from the deeply negative levels seen in prior quarters, indicates that the company is still not generating any return on its invested capital, as reported in recent financial statements.
The shift from a negative ROIC to breakeven is driven by the initial recognition of YARTEMLEA revenue, not by a fundamental improvement in capital efficiency. The company's asset base remains heavily weighted towards intangible assets and goodwill from past acquisitions, which do not generate returns without successful product commercialization. Until narsoplimab or OMS906 achieve market approval, ROIC is likely to remain depressed, reflecting the ongoing consumption of capital without commensurate returns.
Liquidity Position is Critically Fragile
With a current ratio of 1.95 and a quick ratio of 1.94 in Q2 2026, Omeros appears to have adequate short-term liquidity, but this is misleading given the reported cash balance of only $2.0 million, which represents less than one week of R&D expenditure.
The high current and quick ratios are driven by a large accounts receivable balance, likely tied to the YARTEMLEA launch, rather than by cash. The near-identical values for the current and quick ratios suggest minimal inventory, which is consistent with a royalty-based revenue model. However, the extreme mismatch between the reported ratios and the actual cash position indicates that the company's liquidity is entirely dependent on the timely collection of receivables and the ability to raise additional capital.
The Misleading Promise of the Forward P/E
The forward P/E ratio of 21.11x is the most commonly misapplied metric for Omeros, as it obscures the company's true financial risk by implying a level of earnings stability that does not exist for a pre-profit biotech with a $2.0 million cash balance.
This ratio is misleading because it is based on speculative forward earnings estimates that are highly sensitive to regulatory outcomes and commercial execution. For a company like Omeros, which is still in the early stages of its first commercial launch and faces significant regulatory hurdles for its lead pipeline asset, the forward P/E provides a false sense of valuation security. A more appropriate metric would be a risk-adjusted discounted cash flow analysis that explicitly models the probability-weighted outcomes of its key clinical programs.